While our study provides important insights into the anticancer effects of empagliflozin and its synergistic effects with tamoxifen in the MCF-7 ER + breast cancer cell line, it is important to acknowledge that the use of a single cell line may not fully represent the heterogeneity of ER + breast cancers. Here, ESR1 is linked to breast carcinoma.